Questions (and a Few Answers) Arise as the FDA Approves First Biosimilar

Posted by Ed Schoonveld on Mon, Mar 16, 2015

We live in interesting times. We just saw the approval of Zarxio, the first U.S. biosimilar product of Neupogen (filgrastim). What it means for both products is still uncertain, as U.S. rules for biosimilars are still evolving. Key questions have been the convention of proprietary names for biosimilars and the interchangeability between original and biosimilar. These two questions may be an important driver of views and actions from payers and prescribers.


>
Read More

Are Global Markets Free-Riding on the United States?

Posted by Ed Schoonveld on Mon, Feb 23, 2015

In reaction to my recent blog on the cost of drug development, Peter raised the “global free-riding” problem and asked for my perspective. The global free-riding problem is the perception that the United States is subsidizing drugs for the rest of the world due to high drug prices in the United States compared with other countries.


>
Read More

Cost of Developing a New Drug

Posted by Ed Schoonveld on Fri, Dec 19, 2014

Research and development (R&D) cost for prescription drugs is often a central theme to the drug-pricing debate. It is indeed one of the reasons why drug cost can sometimes be very high. The argument never seems to really hold water with anybody, particularly for individual drugs that exceed market expectations, where payers and the public sometimes argue that there should be opportunities to lower price. The Price of Global Health (Second Edition) goes more in depth on the drug-pricing debate and on why prescription drugs are different from other products. So what is new in this discussion?


>
Read More

New Edition: The Price of Global Health

Posted by Ed Schoonveld on Wed, Dec 03, 2014

More than three years have passed since The Price of Global Health was first published. As the book’s author, I have been delighted with the enthusiastic reactions, which as I mentioned in the book’s preface, has made me wonder why I did not write it before. Meanwhile, the prescription drug market has continued to rapidly change with the introduction of the Affordable Care Act (Obamacare) in the United States, AMNOG in Germany and many other changes in payer systems worldwide. Also, I have received a lot of interest in addressing some additional topics related to pharmaceutical market access and pricing. Today, I am happy to announce the imminent publication of a second edition of The Price of Global Health.


>
Read More